Skip to main content
Fig. 3 | Reproductive Biology and Endocrinology

Fig. 3

From: Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)

Fig. 3

Follicle size after fixed-dose phase (Stimulation Day 6) and follicles >14 mm after dose adaptation (Day of hCG Administration) (ITT population). In Ovaleap® group, n = 153 at both time points; in Gonal-f® group, n = 146 on Day 6 and 144 on hCG day; error bars show standard deviation

Back to article page

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us